These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36558033)

  • 21. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
    Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
    Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
    Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.
    Yao H; Ren Y; Wu F; Liu J; Li J; Cao L; Yan M; Li X
    Eur J Med Chem; 2024 Sep; 275():116590. PubMed ID: 38908104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
    Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
    Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR
    Fang H; Wu Y; Xiao Q; He D; Zhou T; Liu W; Yang CH; Xie Y
    Bioorg Med Chem Lett; 2022 Sep; 72():128729. PubMed ID: 35413415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel anilinopyrimidine derivatives as potential EGFR
    Guo Y; Gao B; Gao P; Fang L; Gou S
    Bioorg Med Chem; 2022 Sep; 70():116907. PubMed ID: 35810715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR
    Park HR; Kim TM; Lee Y; Kim S; Park S; Ju YS; Kim M; Keam B; Jeon YK; Kim DW; Heo DS
    J Thorac Oncol; 2021 Nov; 16(11):1859-1871. PubMed ID: 34242789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC.
    Hu L; Shi S; Song X; Ma F; Ji O; Qi B
    Eur J Med Chem; 2024 Feb; 265():116074. PubMed ID: 38142512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR
    Wang A; Shuai W; Wu C; Pei J; Yang P; Wang X; Li S; Liu J; Wang Y; Wang G; Ouyang L
    J Med Chem; 2024 Feb; 67(4):2777-2801. PubMed ID: 38323982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational Computational Design of Fourth-Generation EGFR Inhibitors to Combat Drug-Resistant Non-Small Cell Lung Cancer.
    Park H; Jung HY; Kim K; Kim M; Hong S
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33297461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insights into the Overcoming EGFR
    Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
    ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
    Günther M; Lategahn J; Juchum M; Döring E; Keul M; Engel J; Tumbrink HL; Rauh D; Laufer S
    J Med Chem; 2017 Jul; 60(13):5613-5637. PubMed ID: 28603991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
    Obst-Sander U; Ricci A; Kuhn B; Friess T; Koldewey P; Kuglstatter A; Hewings D; Goergler A; Steiner S; Rueher D; Imhoff MP; Raschetti N; Marty HP; Dietzig A; Rynn C; Ehler A; Burger D; Kornacker M; Schaffland JP; Herting F; Pao W; Bischoff JR; Martoglio B; Alice Nagel Y; Jaeschke G
    J Med Chem; 2022 Oct; 65(19):13052-13073. PubMed ID: 36178776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.